Evommune, Inc. (“Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that on October 17, 2025, it filed a registration statement on FormS-1with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the commencement of a proposed initial public offering of its common stock. […]
— Third quarter income from operations of $285.9 million (excluding special items, third quarter loss from operations of $27.1 million) — Declared quarterly dividend of $0.275 per share — PBF closed sale of terminal assets for $175.4 million — PBF to receive a second unallocated installment of $250 million related to the Martinez Refinery Fire
Completed rolling NDA submission for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC On track to report topline pivotal data for neladalkib in TKI pre-treated advanced ALK-positive NSCLC by year-end 2025 Strong financial position with operating runway anticipated into 2028 Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase
The report”High Purity Gas Marketby Type (High Atmospheric Gas, Noble Gas, Carbon Gas, Other Gases), Storage & Distribution and Transportation, Function, Manufacturing Process, End-use Industry, and Region – Global Forecast to 2030″, high purity gases marketis expected to reach USD 52.78 billion by 2030 from USD 37.46 billion in 2025, at a CAGR of 7.1%
CMS Energy announced today reported earnings per share of $0.92 for the third quarter of 2025, compared to $0.84 per share for 2024. The company's adjusted earnings per share for the third quarter were $0.93, compared to $0.84 per share for the same quarter in 2024. For the first nine months of the year, the
Returned $136 million to Stockholders During Third Quarter Announces Increased 2025 Guidance BorgWarner Inc. (NYSE: BWA) today reported third quarter results and increased 2025 guidance. https://mma.prnewswire.com/media/2336418/BorgWarner_Logo_v2.jpg Third Quarter Results and Business Update — BorgWarner's (the “Company”) U.S. GAAP net sales increased approximately 4.1%, while organic sales increased approximately 2.1%, year-over-year compared with third quarter 2024.
Durable results driven by innovation-led volume growth and effective cost management Full year outlook reflects solid performance in a dynamic operating environment Kimberly-Clark Corporation (Nasdaq: KMB) today reported third quarter 2025 results driven by resilient consumer demand for the company's brands, the introduction of pioneering innovative new products, and leveraging sustained, industry-leading productivity. “The operating
(NASDAQ:AGIO), $12.9 million in third quarter PYRUKYND(R) (mitapivat) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026 RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch
(NASDAQ:AMST), DETROIT, Oct. 30, 2025 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading developer of AI-powered enterprise solutions, announces a 69% QoQ increase in revenue even as it reduced its spending. Amesite also reported expanding its customer base and offerings to post-acute health businesses across the U.S. The Company described these results and its
(NASDAQ:DGICA),(NASDAQ:DGICB), MARIETTA, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) — Donegal Group Inc. (NASDAQ: DGICA) and (NASDAQ: DGICB) today reported its financial results for the third quarter and first nine months of 2025. Significant Items for third quarter of 2025 (all comparisons to third quarter of 2024): Net premiums earned decreased 3.4% to $229.8 million Combined